EA201790558A1 - Композиция с пониженной иммуногенностью - Google Patents

Композиция с пониженной иммуногенностью

Info

Publication number
EA201790558A1
EA201790558A1 EA201790558A EA201790558A EA201790558A1 EA 201790558 A1 EA201790558 A1 EA 201790558A1 EA 201790558 A EA201790558 A EA 201790558A EA 201790558 A EA201790558 A EA 201790558A EA 201790558 A1 EA201790558 A1 EA 201790558A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
human
reduced immunogenicity
polyclonal antibodies
pathogen
Prior art date
Application number
EA201790558A
Other languages
English (en)
Inventor
Одиль Дюво
Жан-Поль Сулийу
Original Assignee
Ксенотера
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ксенотера filed Critical Ксенотера
Publication of EA201790558A1 publication Critical patent/EA201790558A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/18—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with another compound as one donor, and incorporation of one atom of oxygen (1.14.18)
    • C12Y114/18002—CMP-N-acetylneuraminate monooxygenase (1.14.18.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01087—N-Acetyllactosaminide 3-alpha-galactosyltransferase (2.4.1.87), i.e. alpha-1,3-galactosyltransferase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/108—Swine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Настоящее изобретение относится к поликлональным антителам, по меньшей мере к одному нечеловеческому биологическому патогену или по меньшей мере к одной молекуле, полученной из упомянутого патогена, к организму человека или животного, не являющегося человеком, где указанные поликлональные антитела лишены антигенной детерминанты, выбранной из группы, содержащей (i) N-гликольнейраминовую кислоту (Neu5Gc) и/или (ii) α-1,3-галактозу, и их применению в качестве лекарственного препарата.
EA201790558A 2014-10-15 2015-10-15 Композиция с пониженной иммуногенностью EA201790558A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14306633 2014-10-15
PCT/EP2015/073892 WO2016059161A1 (en) 2014-10-15 2015-10-15 Composition with reduced immunogenicity

Publications (1)

Publication Number Publication Date
EA201790558A1 true EA201790558A1 (ru) 2017-08-31

Family

ID=51842458

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790558A EA201790558A1 (ru) 2014-10-15 2015-10-15 Композиция с пониженной иммуногенностью

Country Status (8)

Country Link
US (1) US11725044B2 (ru)
EP (2) EP3207055A1 (ru)
CN (1) CN107001449A (ru)
AU (1) AU2015332634B2 (ru)
CA (1) CA2963437A1 (ru)
EA (1) EA201790558A1 (ru)
WO (1) WO2016059161A1 (ru)
ZA (1) ZA201702401B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014170867A1 (en) * 2013-04-18 2014-10-23 Institut National De La Sante Et De La Recherche Medicale Composition with reduced immunogenicity
EP3510861A3 (en) * 2017-12-22 2019-09-25 Avantea SRL Hypoallergenic food and medical products from genome edited livestock
CN108707607A (zh) * 2018-06-08 2018-10-26 邵玉芹 一种能特异性检测ev71病毒的适配体及试剂盒
CN109042489A (zh) * 2018-06-13 2018-12-21 凌云县沙里双龙养兔场 一种兔子的饲养方法
CN109329202A (zh) * 2018-09-28 2019-02-15 贵州大学 一种有效抑制n-羟乙酰神经氨酸合成的方法
AU2020266993A1 (en) * 2019-04-30 2022-01-06 Xenothera Association of polyclonal antibodies and anti-PD1 or anti-PDL1 antibodies for the treatment of cancer
CN110863031A (zh) * 2019-09-29 2020-03-06 安徽医科大学第一附属医院 一种检测布鲁菌病治疗效果的标志物及其应用
EP4267610A1 (en) 2020-12-23 2023-11-01 Xenothera Composition of pig polyclonal antibody for its use to treat and/or prevent antibody-dependent macrophage pro-inflammatory cytokine release in a passive anti-infectious immunotherapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
DE3775783D1 (de) 1986-01-14 1992-02-20 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
FR2629347B1 (fr) 1988-04-01 1991-06-14 Merieux Inst Procede de preparation d'un serum antilymphocytaire par immunisation d'animaux a l'aide d'un clone de lymphoblaste t humain, et serum antilymphocytaire ainsi obtenu
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
JPH07155194A (ja) 1993-12-10 1995-06-20 Teijin Ltd タンパク質の精製法
EP1400592A1 (en) * 1996-10-31 2004-03-24 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
EP1465481A4 (en) 2001-12-21 2007-09-12 Univ Missouri KNOCK-OUT PORK AND METHODS OF MAKING THE SAME
ES2319636T3 (es) 2002-02-05 2009-05-11 Genentech, Inc. Purificacion de proteinas.
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
NZ536341A (en) * 2002-05-17 2008-05-30 Kirin Holdings Kk Transgenic ungulates capable of human antibody production
KR101115240B1 (ko) * 2002-08-13 2012-03-02 햅토젠 리미티드 항-락톤 또는 락톤 유도된 시그널 분자 항체를 이용한 감염성 세균 질환의 치료 방법
AU2004215653B2 (en) 2003-02-28 2011-03-17 Lonza Biologics Plc. Antibody purification by protein A and ion exchange chromatography
NZ554824A (en) * 2004-10-22 2010-10-29 Revivicor Inc Porcines that lack endogenous antibody chains and express exogenous immunoglobulins
US8232448B2 (en) 2005-06-08 2012-07-31 The Regents Of The University Of California Transgenic mouse with a homozygous mutation in the CMAH gene
WO2007101441A1 (en) 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
EP2815768A3 (en) 2006-04-05 2015-01-14 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20100150942A1 (en) * 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
FR2942233B1 (fr) 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
US20100330102A1 (en) 2009-06-26 2010-12-30 Wezen Biopharmaceuticals Srl A Socio Unico Immunoglobulin preparation for the treatment of hiv-1 infection
WO2011036539A1 (en) * 2009-09-23 2011-03-31 Borody Thomas J Therapy for enteric infections
US20120027771A1 (en) * 2010-04-12 2012-02-02 Cantor Thomas L Affinity purified human polyclonal antibodies against viral, bacterial and/or fungal infections and methods of making and using the same
PT2643017T (pt) * 2010-11-23 2019-09-05 Pantheryx Inc Composições e métodos para tratamento em aplicações clínicas de amplo espetro, misturadas ou indiferenciadas
ES2671733T3 (es) * 2011-06-30 2018-06-08 Sigma Aldrich Co. Llc Células deficientes en ácido CMP-N-acetilneuramínico hidroxilasa y/o glucoproteína alfa-1,3-galactosil transferasa
US20140115728A1 (en) * 2012-10-24 2014-04-24 A. Joseph Tector Double knockout (gt/cmah-ko) pigs, organs and tissues
WO2014170867A1 (en) 2013-04-18 2014-10-23 Institut National De La Sante Et De La Recherche Medicale Composition with reduced immunogenicity

Also Published As

Publication number Publication date
CN107001449A (zh) 2017-08-01
AU2015332634B2 (en) 2020-05-14
AU2015332634A1 (en) 2017-04-27
ZA201702401B (en) 2018-08-29
WO2016059161A1 (en) 2016-04-21
US20170240616A1 (en) 2017-08-24
EP3613764A1 (en) 2020-02-26
CA2963437A1 (en) 2016-04-21
US11725044B2 (en) 2023-08-15
EP3207055A1 (en) 2017-08-23

Similar Documents

Publication Publication Date Title
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
EA201791485A1 (ru) Анти-cd47-антитела и их применения
CL2019000067A1 (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos.
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
EA202092435A2 (ru) Моноклональные антитела против bcma
EA201991715A1 (ru) Композиции, содержащие антитело к pdl1
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201291157A1 (ru) Мультивалентные вакцины с синтетическими наноносителями
PH12016501366A1 (en) Novel anti-baff antibodies
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
EA201201016A1 (ru) Антидоты антикоагулянтов
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
MX2018015268A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
BR112015025748A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2023006416A (es) Anticuerpos, usos y metodos.
BR112017001417A2 (pt) variantes de proteína de ligação ao fator h e métodos para uso das mesmas
TR201910573T4 (tr) Staphylococcus aureus'a karşı bağışıklık kazandırmak için stabilize edilmiş proteinler.
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
BR112019010128A2 (pt) proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas
BR112018002382A2 (pt) novos anticorpos anti-gvpi humano e usos dos mesmos